Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Reshma Saujani,
Girls Who Code
Fixing Tech’s Gender Gap [Entire Talk]
When it comes to gender equity, the technology sector still has a lot of work to do.
Reshma Saujani,
Girls Who Code
Fixing Tech’s Gender Gap [Entire Talk]
When it comes to gender equity, the technology sector still has a lot of work to do.
James Reinhart,
thredUP
Scaling Sustainable Fashion [Entire Talk]
Building a marketplace business is inherently challenging, but the upsides are huge if you can find a new way of connecting supply and demand.
James Reinhart,
thredUP
Scaling Sustainable Fashion [Entire Talk]
Building a marketplace business is inherently challenging, but the upsides are huge if you can find a new way of connecting supply and demand.
Lynda Kate Smith,
mParticle
Marketing for Entrepreneurs [Entire Talk]
Even the greatest technology doesn’t sell itself.
Lynda Kate Smith,
mParticle
Marketing for Entrepreneurs [Entire Talk]
Even the greatest technology doesn’t sell itself.
